HSP90 inhibitors diminish PDGF-BB-induced migration of osteoblasts via suppression of p44/p42 MAP kinase

• Published in: Biomedical Research 2019/08/01, Vol.40(4), pp.169-178
• Main Authors: KAWABATA, Tetsu, TOKUDA, Haruhiko, FUJITA, Kazuhiko, MATSUSHIMA-NISHIWAKI, Rie, SAKAI, Go, TACHI, Junko, HIOKI, Tomoyuki, KIM, Woo, IIDA, Hiroki, OTSUKA, Takanobu, KOZAWA, Osamu
• Format: Article
• Language: English
• Subjects: Animals; Assaying; Attenuation; Becaplermin - pharmacology; Benzamides - pharmacology; Benzoquinones - pharmacology; Biomedical materials; Bone remodeling; c-Jun protein; Cell activation; Cell adhesion & migration; Cell Line; Cell migration; Cell Movement - drug effects; Geldanamycin; Growth factors; Heat shock proteins; HSP90 Heat-Shock Proteins - antagonists & inhibitors; HSP90 Heat-Shock Proteins - metabolism; Hsp90 protein; Inhibitors; Isoindoles - pharmacology; JNK protein; Kinases; Lactams, Macrocyclic - pharmacology; MAP kinase; MAP Kinase Signaling System - drug effects; Mice; Mitogen-Activated Protein Kinase 1 - metabolism; Mitogen-Activated Protein Kinase 3 - metabolism; Osteoblasts; Osteoblasts - metabolism; Osteoclasts; Phosphorylation; Phosphorylation - drug effects; Platelet-derived growth factor; Platelet-derived growth factor BB; Transcription factors; Wound healing
• ISSN: 0388-6107; 1880-313X
• DOI: 10.2220/biomedres.40.169

Migration of osteoblasts to the sites resorbed by osteoclasts is an essential step in bone remodeling. However, the exact mechanism of osteoblast migration is still not known. We have shown that platelet-derived growth factor (PDGF)-BB induces the migration of osteoblast-like MC3T3-E1 cells through the activation of p38 mitogen-activated protein (MAP) kinase, c-Jun N-terminal kinase (JNK) and p44/p42 MAP kinase. Evidence is accumulating that heat shock protein 90 (HSP90) acts as a central regulator of proteostasis under stress conditions and physiological cell functions. In the present study, using transwell cell migration assay and wound-healing assay, we investigated the involvement of HSP90 in the PDGF-BB-stimulated migration of MC3T3-E1 cells, and the underlying signaling mechanism estimated by Western blot analyses. Onalespib, an HSP90 inhibitor, significantly reduced the PDGF-BB-stimulated migration evaluated by the two types of migration assays. The cell migration was also suppressed by geldanamycin, another type of HSP90 inhibitor. Onalespib markedly attenuated the PDGF-BB-elicited phosphorylation of p44/p42 MAP kinase without affecting that of p38 MAP kinase or JNK. In addition, the phosphorylation of p44/p42 MAP kinase by PDGF-BB was reduced by geldanamycin. Taken together, these results strongly suggest that HSP90 inhibitors suppress the PDGF-BB-induced osteoblast migration through the attenuation of p44/p42 MAP kinase activity.